Adding linagliptin to glimepiride treatment reduces some measures of glycemic variability and improves glycemic control in patients with HNF1A-MODY, indicate findings from the GLIMLINA trial.
Islet autoantibody negativity plus mild hyperglycemia and a family history of diabetes can be used to identify children newly diagnosed with diabetes who should undergo genetic testing for maturity-onset diabetes of the young, study findings indicate.
Allocating people with diabetes to one of five previously described data-driven clusters may help to identify those at high immediate risk for developing diabetic neuropathy or non-alcoholic fatty liver disease, say researchers.